Trials / Completed
CompletedNCT00734097
A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)
An Open Label, Multicentre Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 314 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a change in treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Esomeprazole 40 mg | Once a day |
| PROCEDURE | Physical Exam | every visit |
| OTHER | Quality of Life Questionnaires | every visit |
| PROCEDURE | pregnancy test, if applicable | as needed |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2008-08-13
- Last updated
- 2012-10-10
- Results posted
- 2012-10-10
Locations
10 sites across 4 countries: Argentina, Chile, Colombia, Venezuela
Source: ClinicalTrials.gov record NCT00734097. Inclusion in this directory is not an endorsement.